Thomson A W
Immunol Today. 1989 Jan;10(1):6-9. doi: 10.1016/0167-5699(89)90057-1.
FK-506 is a recently discovered immunosuppressive agent that, although structurally quite distinct from cyclosporin A (CsA), shares many of its properties. These include interference with production of interleukin 2 (IL-2) and other lymphokines, lack of myelotoxicity and the induction of transplantation tolerance following administration of short courses to allografted rats. Compared with CsA, however, FK-506 is much more potent and the two agents can act synergistically both in vivo and in vitro. However, severe side effects of FK-506 have been reported in dogs and baboons, although not in rats. On the basis of recently published findings. Angus Thomson reviews the immunological properties of FK-506 and assesses its potential in the light of the impact already made by CsA in both the laboratory and clinic.
FK-506是一种最近发现的免疫抑制剂，尽管其结构与环孢菌素A（CsA）有很大不同，但具有许多共同特性。这些特性包括干扰白细胞介素2（IL-2）和其他淋巴因子的产生、无骨髓毒性以及在给同种异体移植大鼠短期给药后诱导移植耐受。然而，与CsA相比，FK-506的效力要强得多，这两种药物在体内和体外都能协同作用。不过，虽然在大鼠中未发现，但在狗和狒狒中已报道了FK-506的严重副作用。基于最近发表的研究结果，安格斯·汤姆森综述了FK-506的免疫学特性，并根据CsA在实验室和临床中已产生的影响评估了其潜力。
